The European Medicines Agency says that people who have previously had capillary leak syndrome must not be given AstraZeneca PLC/Oxford University’s COVID-19 vaccine, Vaxzevria, and that CLS should be added to the vaccine’s product information as a new side-effect.
The agency’s drug safety committee (the PRAC) carried out an in-depth review of six cases of CLS in people who...







